Treating hyperglycemia may improve patient outcome, but is a clinical challenge.
INTRODUCTION
Hyperglycemia in patients with acute cardiac conditions is associated with increased mortality compared to normoglycemia in the same condition (1) . Furthermore, lower mortality rates have been observed in hyperglycaemic patients presenting with acute myocardial infarction receiving insulin therapy (2) . Protocols for regulation of glucose levels on high care and intensive care facilities have been introduced in many hospitals. However, compliance to such protocols may be inadequate, especially when other treatments interfere with the timing of measurements and/or time to calculate new insulin infusion rates. The use of a computerized clinical decision support system (CDSS) for glucose regulation was shown to improve both protocol adherence and achievement of glycemic targets when compared to a paper guideline in a mixed surgical / medical intensive care unit (3) . Prior to the current study, glucose levels at our Intensive Cardiac Care Unit (ICCU) were inadequately controlled, and adherence to the existing paper protocol was suboptimal. Therefore, a web based CDSS for glucose control was developed (4, 5) .
The initial CDSS consisted of an automated version of the existing paper protocol. A touch-screen monitor on the ICCU displays a board view of all currently admitted patients. New glucose values are automatically retrieved from the laboratory and displayed along with insulin infusion rates and patient data from the Patient Data Management System (PDMS). For each new glucose value, a pop-up is displayed with an advice for adaptation of the insulin infusion rate and timing of the next glucose measurement as appropriate. Temporal trends in glucose levels and insulin dosage are displayed as an additional aid. Following implementation, improvements were observed in protocol compliance and achievement of glycemic targets, but there was ample room for further improvement. Using feedback from nurses, physicians and new evidence from literature, two modifications of the CDSS protocol were made [1. ] to account for a decrease in glucose levels over time and [2. ] widening of glucose target levels as well as addition of a mealtime protocol since implementation of the CDSS. The aim of the current study was to evaluate the impact of these protocol modifications on protocol compliance and achievement of target glucose levels in the ICCU. The study was conducted at the ICCU of the Erasmus University Medical Center in Rotterdam, the Netherlands. The unit consists of 8 beds with a 1:1-1:2 nurse to patient ratio and 1400-1700 admissions per year. Patients admitted included cardiac, non-surgical patients requiring intensive (cardiac) care. The nursing staff uses a web-based PDMS (ChartAssist, Draeger Medical, Andover, MA).
Insulin protocol characteristics and modifications

Protocol 1
During the first study period, a simple sliding scale protocol with a target glucose range of 4.5-7.0 mmol/l (81-126 mg/dl) was used. Copies of the protocol were available at the bedside of each patient and at the main ICCU desk. An excerpt of the protocol is given in Figure 1a . The protocol was nurse-driven, and initiated for all patients with an acute myocardial infarction or with a history of diabetes; for all other patients with elevated glucose levels a physician was consulted first. For each glucose value, the protocol provided an advice regarding the subsequent insulin infusion rate and the time of the next measurement. The glucose level was determined in the hospital central laboratory from a venous or arterial blood sample.
Protocol 2
Based on user feedback from the first period (nurses were asked to register reasons for non-compliance in the PDMS), changes were made to the protocol to manage insulin therapy in the case of decreasing glucose levels. This modification aimed to prevent hypoglycaemic episodes and facilitate achievement of a more stable normoglycemic state. In the case of decreasing glucose values, the protocol advised more frequent measurements and/or a decrease in insulin dosage. The modifications were made to the CDSS and the paper copies. Nurses were informed of the changes by a newsletter and plenary as well as individual instructions.
Protocol 3
The user feedback from the second period revealed that the protocol did not account for increased insulin demands around mealtimes, in patients allowed and capable of eating. Therefore, a separate protocol was developed regarding the administration of insulin around mealtimes. As the necessary information regarding nutrition was not available in the PDMS, this specific protocol was used as a paper version only.
In addition to the advice regarding the administration of insulin around meals, the new protocol also applied a higher threshold for initiating insulin therapy (10.1 instead of 7.1 mmol/l). Furthermore, the target range was widened (from 4.5 -7.0 to 4.1 -8.0 mmol/l). This was done following the results of the NICE-SUGAR trial which demonstrated no additional benefit to strict glycemic regulation (6) . Excerpts from protocol 3 are given in figure 1b (continuous insulin infusion) and 1c (mealtime insulin). An overview of the different protocol characteristics is given in Table 1 .
Glucose Clinical Decision Support System (CDSS)
The design of the CDSS for glucose control has been described in detail elsewhere (4, 5, 7) . Briefly, using a touch-screen, a board view display was developed showing all eight ICCU beds. Glucose values are represented for each bed by colored bars; bars are green when the value is within the target range, and red when too high or too low. The insulin infusion rate is represented by a black line. Bars are displayed for measurements over the last 15 hours. When a new glucose value is reported by the lab, a pop-up is displayed with the value and an algorithm-generated advice with respect to the adjustment in insulin infusion rate and the time for the next glucose measurement. This algorithm is based on the glucose protocols as described above. The pop-up can be closed with a finger press. Additionally, the last pop-up can be recalled by touching the patient name. The glucose value and insulin infusion rate at a given time can be retrieved by touching the respective bar. 
Data collection
Patient demographics, admission diagnoses and medical history were registered in the PDMS. Glucose values were registered in the hospital information system. Insulin infusion rates and reasons for not complying with the protocol were retrieved from the PDMS. For each patient, the average glucose during admission was calculated (using the area under the curve methodology with linear interpolation (8)). Hypoglycaemic episodes were defined as any value lower than 4.0 mmol/l; severe hypoglycaemia was defined as any value lower than 3.3 mmol/l. Protocol compliance with respect to the timeliness of measurement was determined as the proportion of measurements done within the advised time from the previous measurement, with a 10% margin. Protocol compliance with respect to insulin dosage was determined using the difference between the actual insulin infusion rate and the recommended rate between the glucose measurement generating the advice and the subsequent measurement. Evaluation of timeliness was done for all measurements except for the first; evaluation of correct insulin dosage was done for all measurements except for the last. Reasons for non-compliance were collected and stored in a database. First, nurses were instructed to enter the reason for deviation from the protocol into the electronic charting system, they could also choose to write down comments in a notebook present next to the touch-screen. The study investigator (JL) was available for consultation on weekdays and by phone over weekends and nights to answer questions and receive feedback.
Statistical analysis
Statistical analysis was done with SPSS 15.0 (Chicago, USA). Continuous data were expressed as mean with Standard Deviation (SD) or median values with interquartile range (IQR), as appropriate. Student's t-test and analysis of variance were used to analyze continuous data between the groups. Differences between proportions were compared using the χ 2 test. P<0.05 was considered statistically significant.
RESULTS
Patient characteristics
During the study period, glucose was measured in 1898 patients; 1225 had at least two measurements during admission and were included in the study; 269 in group 1; 814 in group 2 and 142 in group 3. Patient characteristics are shown in Table 2 . Age was 64±14 years. The proportion of males was slightly higher in group 1 vs. group 2 (72 vs. 64%, P=0.02) and group 3 (72 vs. 62%, P = 0.051), also the proportion of patients with renal disease was higher in group 1 vs. groups 2 and 3 (14% vs. 9% and 8%, P=0.04). There were more diabetics and patients with previous myocardial infarction, and less patients with heart failure in groups 2 and 3 vs. group 1, however these differences did not reach statistical significance. Clinical characteristics are shown in Table 3 . Overall, 53% of the patients were admitted for evaluation of an acute coronary syndrome. A diagnosis of acute myocardial infarction was established in 35% of the patients. From groups 1 to 3, an increase was seen in the percentage diagnosed with stable angina and cardiac arrest, and a decrease in heart failure and valvular disease although the overall APACHE-2 score as a measure of disease severity did not change. Duration of admission, admission glucose levels, number of glucose measurements and average glucose during admission were similar across the groups. 
Glucose levels
Average glucose levels during admission are displayed by group in Figure 2 . As could be expected, based on the protocol modifications, there was a trend towards higher glucose levels from Group 1 to 3. The proportion of patients with an average glucose within the "normal" range (<8 mmol/l) was lower in groups 2 and 3 (P<0.001). There was also a decrease in the incidence of hypoglycaemic events over time, however this trend did not reach statistical significance. The incidence of severe hypoglycaemia (<3.3 mmol/l) was low in all groups (<1.2%).
Care Improvement
Evaluation of glucose protocol modifications on the ICCU 
Protocol adherence
In total, 19,153 measurements were analyzed (17,928 after omission of the first and last measurement for evaluation of timeliness and insulin dosage respectively). The number of measurements per patient was slightly higher in group 3 compared to groups 1 and 2 (16.7 vs. 14.5; P=NS). Compliance to the insulin protocol with respect to timeliness of the glucose measurement was highest with protocol 3 and lowest with protocol 2 (52% vs. 44%, P <0.001, figures 3 and 4) . Compliance with the recommended insulin dosage was highest for protocol 3 and lowest for protocol 2 (71% vs. 57%, P <0.001). Deviation from protocol advice Nurse-reported reasons for deviating from the protocol advice (either time of measurement or dosage of insulin) are displayed in Table 4 . The reporting incidence as percentage of the total number of glucose measurements decreased from 3.3% in group 1 to 2.0% and 0.9% in groups 2 and 3 respectively. Overall, changes in nutrition were the most frequent reason for declination: less intake or stopping of enteral feeding during the night (15.3%), a change in enteral feeding (10.0%) and meals (9.5%). Deviation to account for a decrease in glucose values was reported more frequently for protocol 1 than for protocols 2 and 3. The most frequent reported reasons for deviating from protocol 3 were highly variable glucose levels and night-time changes in nutrition; no deviations were reported to accommodate for meals and/or a decrease in glucose levels in this group. 
Insulin dose
DISCUSSION
We hypothesized that the modifications to the protocols would lead to an increase in number of patients with an average glucose in the "normal" range (<8 mmol/l), and an increase in protocol compliance. Deviation from the protocol advice in the first protocol occurred in more than a third of the instances: a main reason was to prevent hypoglycaemia when glucose levels were decreasing. Therefore the first modification was to manage decreasing glucose levels by advising lower insulin dosages and more frequent measurements to reduce the risk of hypoglycemia. The incidence of hypoglycemia was indeed lower in group 2 vs. group 1, although this did not reach statistical significance. However, the lower insulin dosages, in combination with more frequent measurements resulted in more detected hyperglycemic episodes. Also, the workload for nurses increased, which can explain the lower compliance with protocol 2 vs. protocol 1, especially regarding the timeliness of the measurements.
After implementation of the second protocol, the most frequent reason for deviation was to regulate glucose levels around mealtimes. Therefore, in protocol 3 we introduced a specific insulin protocol to improve glucose regulation around mealtimes. Indeed, the reporting incidence of protocol deviation in the last group was lower, and compliance was higher, indicating that this protocol best fit the nursing workflow. Also in the third protocol, a higher glucose threshold for initiating insulin treatment was used of 10 mmol/l instead of 8 mmol/l, and the target range was widened from 4.5 -7 mmol/l to 4 to 8 mmol/l. These changes were made following the results of the NICE-SUGAR trial (6) and subse-(6) and subseand subsequent modifications in the ACC-STEMI guidelines (9) . These changes explain the higher glucose levels and fewer hypoglycemic episodes in the final study group.
This study describes a "real-life" experience of modifying a computerized ICCU insulin protocol to improve glucose regulation and compliance and demonstrates that achieving glucose control is challenging indeed. Several factors make it difficult to design a uniform protocol for all patients: ideally one would design different protocols for intubated / non intubated patients, for those receiving no food, enteral feeding and normal intake, for patients with or without insulin dependent diabetes. In addition to these factors, the severity of disease in ICCU patients varies greatly and many patients recover over time which provides an additional challenge for optimal glucose management. Although the goals of the protocol modifications are reached, at least in part, in the presented study, the changes are subtle and take time to become apparent.
Computerized insulin protocols for glycemic control
Many different glucose protocols exist for the intensive care setting and have been reviewed extensively (10, 11) . The CDSS interface in our study was well accepted by the nurses: the visibility was good and improved the awareness to new glucose values once these became available from the laboratory. Although the protocols previously studied varied in design of decision support systems, type of intensive care unit and glycemic outcome measures, most studies report an improvement in glycemic parameters as the result of an automated protocol. However, most of these studies were done in a more uniform patient population (3, 12) . The current study describes a unique, diverse ICCU population consisting of patients experiencing complications after admission for an acute coronary syndrome or other acute cardiac condition, and patients referred from other hospitals for specialized care. Patients with uncomplicated clinical procedures are admitted to the medium care ward or are discharged to the referring center. Our experience shows that it is difficult to establish a protocol that is applicable to all patients at in many different circumstances.
Design of mealtime insulin protocol
Managing insulin therapy for patients around mealtimes is challenging and should depend on individual insulin sensitivity as well as meal composition. Although protocols exist (13, 14) , they proved either to be unsuitable for the ICCU setting or required additional information, not available electronically in the PDMS or charting system. The protocol in group 3 accounts for insulin dosages around mealtimes, but does not do so automatically. The mealtime instructions are displayed on the glucose CDSS touchscreen, but as mealtimes and amount consumed vary by patient, and as this information is not available electronically, this information could not be implemented in the CDSS. Though manual input would be possible to calculate the required insulin dose, the problems associated with data entry errors (15) could well reduce or eliminate the potential benefit of the extra information.
Importance of glucose regulation
Several clinical studies have addressed the relation between glucose lowering therapy and outcomes, however the results are not fully consistent. The first DIGAMI trial demonstrated a significantly reduced mortality at 1 year in patients with an acute myocardial infarction treated with an intensive insulin regimen (16) . The Leuven study found a similar benificial effect of intensive insulin therapy on mortality in intensive care patients (17) . More recent studies, however, were unable to reproduce these effects and illustrate the difficulties in achieving tight glycemic targets (6, 18) . The DIGAMI-2 study did not achieve the expected difference in glucose levels between groups of patients allocated to intensive or less intensive insulin therapy and thus did not demonstrate a clinical advantage of the intensive insulin therapy (18) . In contrast, the NICE-SUGAR study did achieve lower glucose levels in the intervention group, but at the cost of more hypoglycaemic episodes (6) . These studies illustrate the difficulties of implementing an insulin protocol and maintaining compliance with it, and fuel the uncertainty around the optimal insulin treatment strategy and the optimal glucose target levels.
Future directions
Optimal glycemic targets for ICCU patients remain undecided. The initial studies by Malmberg et al. (16) and Van den Berghe et al. (17) showed a survival advantage for tight glycemic control (4 -6mmol/l). However, later studies including DIGAMI 2 (18) and NICE-SUGAR (6) reported increased incidence of hypoglycaemia, and in the case of the NICE-SUGAR trial, an increased mortality in the group with tight glycemic control. Accordingly, the current ACC/AHA guidelines for management of acute myocardial infarction (9) advise a threshold of 10 mmol/l for initiating glucose lowering therapy; and this advice was implemented in the most recent modification of our protocol. Further work is needed to determine optimal glucose targets for the intensive cardiac care setting. Furthermore, the method for glucose measurement can be improved. During the study period, measurements were taken from venous and arterial blood samples, and sent to the laboratory for analysis. This resulted in a delay of 5-25 minutes between time of sampling and the result. The laboratory determination is more accurate than point of care systems, but this advantage may be lost due to the delay and point-of-care measurement may therefore be more appropriate. Ultimately, a closed loop system using a continuous glucose sensor coupled to an algorithm driven insulin pump might provide optimal glycemic regulation. However, even though the accuracy of glucose sensor devices is high, even in the intensive care setting (19, 20) , there is a risk of undetected hypoglycaemia (21) , especially when subcutaneous perfusion is compromised in patients with heart failure or in shock. An intravenous glucose sensor might be more appropriate, as it would not be affected by impaired skin perfusion, but no such system is currently commercially available.
CONCLUSION
Stepwise modification of the ICCU insulin protocol resulted in an increase in protocol compliance with regard to timing of glucose measurements and better adherence to the advised insulin dosage. The percentage of patients achieving a mean glucose level <8mmol/l however, did not increase, illustrating the difficulty in regulating glucose in the ICCU setting. Further work is needed to develop and validate better protocols for blood glucose regulation in the ICCU. A reliable, continuous glucose measurement system may be of great value in this setting.
